Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-1-antitrypsin replacement therapy: current status.

Hatem Abusriwil1, Robert A Stockley

  • 1Lung Investigation Unit, Nuffield House, Queen Elizabeth Hospital, University Hospital Birmingham NHS Trust, Birmingham, UK.

Current Opinion in Pulmonary Medicine
|February 4, 2006
PubMed
Summary

Alpha-1-antitrypsin deficiency treatment with augmentation therapy may slow emphysema progression in some patients. However, large randomized trials are needed to confirm its effectiveness for this genetic disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiency.

The European respiratory journal·2025
Same author

Physiological Small Airways Dysfunction and the Bronchodilator Response in Adults With Asthma and Its Risk Factors: A Retrospective Analysis.

Journal of asthma and allergy·2025
Same author

Bacterial colonisation doubles the risk of exacerbation in alpha-1 antitrypsin deficiency.

Respiratory medicine·2025
Same author

Proposal and Validation of the Minimum Clinically Important Difference in Emphysema Progression.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2025
Same author

Antitrypsin deficiency: still more to learn about the lung after 60 years.

ERJ open research·2024
Same author

A novel <i>in vitro</i> cell model of the proteinase/antiproteinase balance observed in alpha-1 antitrypsin deficiency.

Frontiers in pharmacology·2024

Area of Science:

  • Pulmonology
  • Genetics
  • Pharmacology

Background:

  • Alpha-1-antitrypsin deficiency is a common genetic disorder.
  • It leads to early-onset emphysema and potential liver disease.
  • Current treatment options for emphysema are debated.

Purpose of the Study:

  • To review recent studies on alpha-1-antitrypsin replacement therapy for emphysema.
  • To discuss the pathogenesis, epidemiology, and new therapeutic approaches for the deficiency.

Main Methods:

  • Review of nonrandomized observational studies and meta-analyses.
  • Examination of one small randomized, placebo-controlled trial.
  • Discussion of emerging monitoring methods like CT scans.

Main Results:

Related Experiment Videos

  • Observational studies and meta-analyses suggest reduced forced expiratory volume in 1 second (FEV1) decline.
  • A trend towards preserved lung density was observed in one small RCT.
  • Large randomized trials proving effectiveness are lacking.

Conclusions:

  • Alpha-1-antitrypsin augmentation therapy may benefit specific patient subsets.
  • Further placebo-controlled, randomized clinical trials are essential.
  • Advances in molecular pathology offer new therapeutic targets.